Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Rekah Pharmaceutical Prod's
Operating Income
for the
three
months ended in Mar. 2026 was ₪-0.9 Mil. Rekah Pharmaceutical Prod's Interest Expense for the
three
months ended in Mar. 2026 was ₪-1.6 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Rekah Pharmaceutical Prod's Interest Coverage or its related term are showing as below:
XTAE:REKA's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.75 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Rekah Pharmaceutical Prod Interest Coverage Related Terms
Rekah Pharmaceutical Prod Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XTAE:REKA vs ZTS, UTHR, VTRS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rekah Pharmaceutical Prod's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rekah Pharmaceutical Prod Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rekah Pharmaceutical Prod's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Rekah Pharmaceutical Prod's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Rekah Pharmaceutical Prod did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Rekah Pharmaceutical Prod (XTAE:REKA) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Rekah Pharmaceutical Prod and its competitors. According to the industry distribution chart, Rekah Pharmaceutical Prod ranks #999999 out of 687 companies in the Drug Manufacturers industry.
Is Rekah Pharmaceutical Prod's Interest Coverage too high?
Rekah Pharmaceutical Prod's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Rekah Pharmaceutical Prod ranks #999999 out of 687 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Rekah Pharmaceutical Prod has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rekah Pharmaceutical Prod's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rekah Pharmaceutical Prod ranks #999999 out of 687 companies for Interest Coverage. This places Rekah Pharmaceutical Prod in the lower half of its industry. The industry median Interest Coverage is 12.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Rekah Pharmaceutical Prod and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rekah Pharmaceutical Prod's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rekah Pharmaceutical Prod stock overvalued right now?
Based on GuruFocus' analysis, Rekah Pharmaceutical Prod (XTAE:REKA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₪13.05, compared to a current price of ₪10.30 — trading 21.1% below its estimated fair value. The current Interest Coverage is 0 (At Loss). Rekah Pharmaceutical Prod's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Rekah Pharmaceutical Prod (XTAE:REKA), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rekah Pharmaceutical Prod (XTAE:REKA) Overvalued in 2026?
Based on GuruFocus' analysis, Rekah Pharmaceutical Prod stock appears to be undervalued.
The current stock price of ₪10.30 is trading 21.1% below its estimated GF Value™ of ₪13.05.
GuruFocus considers Rekah Pharmaceutical Prod to be Modestly Undervalued.
Key valuation signals for XTAE:REKA:
Interest Coverage: 0 (At Loss)
GF Value™: ₪13.05 vs. price of ₪10.30 (21.1% below fair value)
No single metric tells the full story. See the XTAE:REKA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rekah Pharmaceutical Prod Ltd is engaged in the manufacturing, importing, marketing, and distribution of pharmaceuticals and cosmetics. It primarily caters to the needs of hospitals, retirement homes, and national medical healthcare services.
57GF Score
Get the complete analysis for XTAE:REKA
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:REKA has been successfully added to your 
